Zobrazeno 1 - 10
of 187
pro vyhledávání: '"Renke, Maas"'
Autor:
Vinitha N. Ragavan, Pramod C. Nair, Natalia Jarzebska, Ramcharan Singh Angom, Luana Ruta, Elisa Bianconi, Silvia Grottelli, Natalia D. Tararova, Daniel Ryazanskiy, Steven R. Lentz, Sara Tommasi, Jens Martens-Lobenhoffer, Toshiko Suzuki-Yamamoto, Masumi Kimoto, Elena Rubets, Sarah Chau, Yingjie Chen, Xinli Hu, Nadine Bernhardt, Peter M. Spieth, Norbert Weiss, Stefan R. Bornstein, Debabrata Mukhopadhyay, Stefanie M. Bode-Böger, Renke Maas, Ying Wang, Antonio Macchiarulo, Arduino A. Mangoni, Barbara Cellini, Roman N. Rodionov
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-16 (2023)
Abstract Dimethylarginine dimethylaminohydrolase 1 (DDAH1) protects against cardiovascular disease by metabolising the risk factor asymmetric dimethylarginine (ADMA). However, the question whether the second DDAH isoform, DDAH2, directly metabolises
Externí odkaz:
https://doaj.org/article/c46891e5d10241cf95a530af2ca4d6b5
Autor:
Roman N. Rodionov, Natalia Jarzebska, Dmitrii Burdin, Vladimir Todorov, Jens Martens-Lobenhoffer, Anja Hofmann, Anne Kolouschek, Nada Cordasic, Johannes Jacobi, Elena Rubets, Henning Morawietz, John F. O’Sullivan, Alexander G. Markov, Stefan R. Bornstein, Karl Hilgers, Renke Maas, Christian Pfluecke, YingJie Chen, Stefanie M. Bode-Böger, Christian P. M. Hugo, Bernd Hohenstein, Norbert Weiss
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-13 (2022)
Abstract Elevated plasma concentrations of asymmetric dimethylarginine (ADMA) are associated with an increased risk of mortality and adverse cardiovascular outcomes. ADMA can be metabolized by dimethylarginine dimethylaminohydrolases (DDAHs) and by a
Externí odkaz:
https://doaj.org/article/674f7781bc76496db8e890262bf3eaf5
Autor:
Arne Gessner, Anna Gemeinhardt, Agnes Bosch, Dennis Kannenkeril, Christian Staerk, Andreas Mayr, Martin F. Fromm, Roland E. Schmieder, Renke Maas
Publikováno v:
Cardiovascular Diabetology, Vol 21, Iss 1, Pp 1-11 (2022)
Abstract Background In patients with type 2 diabetes (T2D) sodium-glucose cotransporter 2 (SGLT-2) inhibitors improve glycaemic control as well as cardiovascular and renal outcomes. Their effects on l-arginine (Arg) related risk markers asymmetric an
Externí odkaz:
https://doaj.org/article/84d0ad9359a24a469e3fdccbc5dcb7ea
Autor:
Ibrahim Musa Yola, Carlee Moser, Meredith S Duncan, Edzard Schwedhelm, Dorothee Atzler, Renke Maas, Juliane Hannemann, Rainer H Böger, Ramachandran S Vasan, Vanessa Xanthakis
Publikováno v:
PLoS ONE, Vol 16, Iss 9, p e0254577 (2021)
BackgroundCirculating levels of the endogenous inhibitor of nitric oxide synthase, asymmetric dimethylarginine (ADMA), are positively associated with the prevalence of metabolic syndrome (MetS) in cross-sectional investigations. It is unclear if circ
Externí odkaz:
https://doaj.org/article/ceb4479eea9640919734a6f24a35e397
Publikováno v:
Metabolites, Vol 12, Iss 4, p 273 (2022)
The uptake transporter NaCT (gene symbol SLC13A5) is expressed in liver and brain and important for energy metabolism and brain development. Substrates include tricarboxylic acid cycle intermediates, e.g., citrate and succinate. To gain insights into
Externí odkaz:
https://doaj.org/article/7d87a520d14c48ce99eb537c8cd85cb6
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-10 (2017)
Abstract Low plasma concentration of L-homoarginine is an independent predictor of cardiovascular events and total mortality. Experimental data indicate that supplementation of L-homoarginine may have protective effects. We aimed to elucidate the mec
Externí odkaz:
https://doaj.org/article/4d049ac98f054c6ba4f7aa0fe4a0e33b
Publikováno v:
PLoS ONE, Vol 14, Iss 3, p e0213747 (2019)
Elevated plasma concentrations of the uremic toxin asymmetrical dimethylarginine (ADMA) and low plasma concentrations of L-homoarginine are independently associated with cardiovascular events and total mortality. Enzymes degrading ADMA [dimethylamino
Externí odkaz:
https://doaj.org/article/22b510ebf3984f9a8160fae8ca5ad634
Autor:
Laura Weisbach, Anna K. Schuster, Michael Hartmann, Pauline Dürr, Melanie I. Then, Wahram Andrikyan, Martin F. Fromm, Renke Maas, Katrin Farker
Publikováno v:
British Journal of Clinical Pharmacology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dfc67986c0ef3fc9e5fd67fb1ae0a20b
https://doi.org/10.1111/bcp.15730
https://doi.org/10.1111/bcp.15730
Publikováno v:
Amino Acids. 54:1101-1108
The cationic amino acid transporter 1 (CAT1/SLC7A1) plays a key role in the cellular uptake or export of l-arginine and some of its derivatives. This study investigated the effect of 113 chemically diverse and commonly used drugs (at 20 and 200 µM)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9abb80253282216923c36b5ebd9131a5
https://doi.org/10.1007/s00726-022-03156-2
https://doi.org/10.1007/s00726-022-03156-2
Autor:
Melanie I. Then, Thomas Tümena, Anna Sledziewska, Karl‐Günter Gaßmann, Renke Maas, Martin F. Fromm
Regulatory authorities put major emphasis on QT (interval)–prolonging properties of new molecular entities. Product information/Summaries of Product Characteristics (SmPCs) of multiple drugs contain warnings or contraindications regarding QT prolon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c9b8b29b88f3e1363d110bd2bdfc660
https://opus4.kobv.de/opus4-fau/frontdoor/index/index/docId/22692
https://opus4.kobv.de/opus4-fau/frontdoor/index/index/docId/22692
